The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Influenza Vaccine for 2018-2019
Revised 10/25/18: Tables 2 and 4 were revised to reflect the FDA's recent approval of Afluria Quadrivalent for person ≥6 months old.

Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old.1 Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.

TIMING — In the US, influenza vaccine should be offered by the end of October and continue to be offered as long as influenza is circulating in the community. In most adults, serum antibody levels peak about two weeks after vaccination.1

COMPOSITION — All seasonal influenza vaccines available in the US contain the same two influenza A virus antigens. Influenza A viruses are responsible for the majority of influenza-related morbidity and mortality, particularly in infants and older adults; influenza A(H3N2) has been associated with the highest rates of morbidity ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1558
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian